K. Grouss

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

Chiaki Tanaka, Ophelia Yin, Venkat Sethuraman et al. · Clinical Pharmacology & Therapeutics · 2009 · 181 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +13

Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants

Chiaki Tanaka, Ophelia Yin, Tom Smith et al. · The Journal of Clinical Pharmacology · 2010 · 68 citations

Medicine, Pharmacokinetics, Pharmacology +13

Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2).

James C. Yao, John D. Hainsworth, Éric Baudin et al. · Journal of Clinical Oncology · 2011 · 21 citations

Medicine, Oncology, Pharmacology +17

Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ALL)

Chiaki Tanaka, Theodore A Smith, Hagop M. Kantarjian et al. · Journal of Clinical Oncology · 2006 · 16 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +13